Patents by Inventor Cohava Gelber

Cohava Gelber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230406906
    Abstract: Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 or TSLP.
    Type: Application
    Filed: July 13, 2023
    Publication date: December 21, 2023
    Inventors: Dana AUSTIN, Cohava GELBER
  • Patent number: 11779630
    Abstract: Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: October 10, 2023
    Assignee: SERPIN PHARMA, LLC
    Inventors: Dana Austin, Cohava Gelber
  • Publication number: 20230138520
    Abstract: The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 4, 2023
    Applicant: CAERUS THERAPEUTICS, INC.
    Inventor: Cohava GELBER
  • Patent number: 11623953
    Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 11, 2023
    Assignees: Caerus Therapeutics, Inc., University of Georgia Research Foundation, Inc.
    Inventors: J. Michael Pierce, Cohava Gelber
  • Publication number: 20220265761
    Abstract: Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation.
    Type: Application
    Filed: July 6, 2021
    Publication date: August 25, 2022
    Inventors: Dana AUSTIN, Cohava GELBER
  • Publication number: 20220119478
    Abstract: Provided herein are constructs comprising a CAR nucleic acid sequence comprising a single chain variable fragment from monoclonal antibody VAC69 for use in stimulating an immune response against solid tumors. The CAR nucleic acid sequence is linked to nucleic acids encoding one or more cytokines, and one or more of a matrix metalloprotease, a PD1 fusion protein, a chemokine receptor, a dominant negative or nonfunctional immunosuppressive or toxic receptor, a FOXP3 inhibitory peptide P60, and a Bi-specific T Cell Engager (BiTE). The constructs can further include one or more of a signal peptide, a self-cleaving peptide, an epitope tag, an internal ribosome entry site (IRES), or a selectable marker.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 21, 2022
    Applicant: CAERUS THERAPEUTICS, CORP.
    Inventors: Mark SPEAR, Cohava GELBER
  • Publication number: 20210371516
    Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 2, 2021
    Applicants: CAERUS THERAPEUTICS, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: J. Michael PIERCE, Cohava GELBER
  • Publication number: 20210369822
    Abstract: We describe peptides and their uses for the treatment of , e.g. acute myocardial infarction and other cytokine storm-associated conditions.
    Type: Application
    Filed: March 29, 2021
    Publication date: December 2, 2021
    Applicant: SERPIN PHARMA, LLC
    Inventor: Cohava GELBER
  • Publication number: 20210188912
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 24, 2021
    Inventors: Soren MOGELSVANG, Cohava GELBER
  • Patent number: 11020462
    Abstract: We describe peptides and their uses for the treatment of, e.g. acute myocardial infarction and other cytokine storm-associated conditions.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 1, 2021
    Assignee: SERPIN PHARMA
    Inventor: Cohava Gelber
  • Patent number: 10899797
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 26, 2021
    Assignee: SERPIN PHARMA, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20200048321
    Abstract: Checkpoint receptors and their cognate ligands are frequently targeted in autoimmune disorders by B and T cells, wherein these adaptive immune responses are likely to significantly contribute to the underlying immunopathology. A novel technology for the clonal elimination of autoreactive B cells that targets checkpoint receptors and their ligands is described herein. One embodiment of this technology is a checkpoint receptor or ligand extracellular domain molecular chimera with an effector domain, which is capable of inducing B cell apoptosis, necrosis, and/or tolerization/anergization: herein, this technology is referred as PantIds (polyclonal anti-idiotypics). In other embodiments, this technology also includes effector molecular chimeras with immunoregulatory cytokines. Novel apoptotic effectors are also described. Methods for the identification of checkpoint receptor/ligand autoreactive B cell responses, construction of PantIds, and their in vitro and in vivo application are also described.
    Type: Application
    Filed: March 23, 2018
    Publication date: February 13, 2020
    Applicant: ORPHEUS BIOSCIENCE INC.
    Inventors: Cohava GELBER, Mark SPEAR, John ABELES
  • Publication number: 20200017550
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: February 26, 2019
    Publication date: January 16, 2020
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20190328852
    Abstract: We describe peptides and their uses for the treatment of, e.g. acute myocardial infarction and other cytokine storm-associated conditions.
    Type: Application
    Filed: August 26, 2016
    Publication date: October 31, 2019
    Applicant: SERPIN PHARMA, LLC
    Inventor: Cohava GELBER
  • Patent number: 10214562
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: February 26, 2019
    Assignee: Serpin Pharma, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Patent number: 9951104
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: April 24, 2018
    Assignee: Serpin Pharma, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20170029465
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 29, 2015
    Publication date: February 2, 2017
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20150290132
    Abstract: Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung, gastrointestinal (GI) tract), little or no immune stimulation. The compositions can mediate cellular delivery of compounds that would otherwise not enter cells and enhance the intracellular delivery of compounds that would otherwise enter cells inefficiently. The methods are carried out by contacting a proximal face of a lipid bilayer or membrane (e.g. the surface of an intact cell) with a complex containing a compound (e.g., a therapeutic agent) and a diketopiperazine (DKP). DKP and the compound are non-covalently associated with each other or covalently bound to each other.
    Type: Application
    Filed: June 26, 2015
    Publication date: October 15, 2015
    Inventors: Cohava Gelber, Kathleen Rousseau
  • Publication number: 20150133375
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 14, 2015
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Patent number: 8975224
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: March 10, 2015
    Assignee: Serpin Pharma, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber